🇺🇸 FDA
Pipeline program

Epo

CHFudanU_NNICU4

Phase 2 small_molecule terminated

Quick answer

Epo for Premature Infant is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Premature Infant
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials